For this purpose, we developed a KIR/HLA pair genotyping to characterize the spectrum of NK-related immune genes in CRC response to FOLFIRI treatment in univariate and multivariate analysis. This evidence concerns the gene KIR3DL1 and colorectal carcinoma.